Psychotropic Medication Prescribing for Neuropsychiatric Comorbidities in Individuals Diagnosed with Autism Spectrum Disorder (ASD) in the UK-Reference-Cited by-同舟云学术

Psychotropic Medication Prescribing for Neuropsychiatric Comorbidities in Individuals Diagnosed with Autism Spectrum Disorder (ASD) in the UK

Published:2019-11-13 Issue:2 Volume:50 Page:625-633
ISSN:0162-3257
Container-title:Journal of Autism and Developmental Disorders
language:en
Short-container-title:J Autism Dev Disord

Author:

Alfageh Basmah H.^ORCID,Man Kenneth K. C.^ORCID,Besag Frank M. C.^ORCID,Alhawassi Tariq M.,Wong Ian C. K.^ORCID,Brauer Ruth^ORCID

Abstract

Abstract Autism spectrum disorder (ASD) is a lifelong disorder. In the UK, risperidone is the only psychotropic medication approved for the management of the behavioural symptoms that may accompany autism. This is a population-based study aimed to provide an evaluation of the changing trend in the incidence and prevalence of ASD and to analyse the pattern of psychotropic medication prescribing in the UK. 20,194 patients with ASD were identified. The prevalence increased 3.3-fold from 0.109 per 100 persons in 2009 to 0.355 per 100 persons in 2016. Approximately one-third of the identified cohort was prescribed at least one psychotropic medication. Although the medications approved to manage the symptoms of ASD are limited, the prescribing of such medications is increasing.

Publisher

Springer Science and Business Media LLC

Subject

Developmental and Educational Psychology

Link

http://link.springer.com/content/pdf/10.1007/s10803-019-04291-8.pdf

Reference28 articles.

1. APA. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington: American Psychiatric Association.

2. Barnett, K., Mercer, S. W., Norbury, M., Watt, G., Wyke, S., & Guthrie, B. (2012). Epidemiology of multimorbidity and implications for health care, research, and medical education: A cross-sectional study. The Lancet,380(9836), 37–43. https://doi.org/10.1016/s0140-6736(12)60240-2.

3. Blak, B. T., Thompson, M., Dattani, H., & Bourke, A. (2011). Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Informatics in Primary Care,19(4), 251–255.

4. British Medical Association, Royal Pharmaceutical Society of Great Britain. (2009). British national formulary: March 2017 (No. 74): Pharmaceutical Pr.

5. Carey, I. M., Hosking, F. J., Harris, T., DeWilde, S., Beighton, C., & Cook, D. G. (2017). An evaluation of the effectiveness of annual health checks and quality of health care for adults with intellectual disability: An observational study using a primary care database. Health Services and Delivery Research. https://doi.org/10.3310/hsdr05250.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estimating life expectancy and years of life lost for autistic people in the UK: a matched cohort study;The Lancet Regional Health - Europe;2024-01

2. Psychotropic Medication Use in Children and Youth with Autism Enrolled in Medicaid;Journal of Autism and Developmental Disorders;2023-12-18

3. Current Status of Psychopharmacological, Neuromodulation, and Oxytocin Treatments for Autism: Implications for Clinical Practice;Advances in Neurodevelopmental Disorders;2023-09-26

4. MANAGEMENT OF AUTISM SPECTRUM DISORDER: A PILOT STUDY IN SAUDI PAEDIATRICS;Military Medical Science Letters;2023-03-29

5. A review of the use of psychotropic medication to address challenging behaviour in neurodevelopmental disorders;International Review of Neurobiology;2023